

Hemgenix® (etranacogene dezaparvovec-drlb) **Medication Precertification Request** Page 1 of 1

(All fields must be completed and legible for precertification review.)

Aetna Precertification Notification Phone: 1-866-752-7021

FAX: 1-888-267-3277

For Medicare Advantage Part B: Please Use Medicare Request Form

Precertification Requested By:			Phone: _	 Fax:	
	☐ Continuation of therapy, Date of last treatment _	1 1			
Please indicate:	Start of treatment: Start date/	_			

☐ Contir	าuation of th	nerapy, Date	of last treatment/	/	1							
Precertification Requested	Phone:			Fax:								
A. PATIENT INFORMATION												
First Name:			Last Name:				DOB:					
Address:			City:				State:	ZIP:				
Home Phone:		Work Phone:	Cell Phone:				Email:					
Patient Current Weight:	lbs or	kgs Patie	ent Height: inches	or	cms Allergie	es:						
B. INSURANCE INFORMATION												
Aetna Member ID #:			Does patient have other coverage?									
Group #:			If yes, provide ID#: Carrier Name:									
Insured:			Insured:					_				
Medicare: ☐ Yes ☐ No If yes, provide ID #:												
C. PRESCRIBER INFORMA	TION											
First Name:						Check One	e):					
Address:			City:				State:	ZIP:				
Phone:	Fax:		St Lic #:	NF	NPI #: DEA #:		T	UPIN:				
Provider Email:			Office Contact Name:	ne:			Phone:					
Specialty (Check one): H	lematologis	t 🗌 Other: _										
D. DISPENSING PROVIDER	R/ADMINIST	RATION INFO	ORMATION									
Place of Administration: Dispensing Provider/Pharmacy: Patient Selected choice												
☐ Self-administered ☐ Physician's Office				☐ Physician's Office ☐ Retail Pharmacy				ıacy				
☐ Outpatient Infusion Center Phone:						cy [☐ Other					
Center Name:				Name:								
Home Infusion Center Phone:				Address:								
Agency Name:							Fax:					
Address:							PIN:					
E. PRODUCT INFORMATIO				'								
Request is for: Hemgenix (ne dezanaryo	vec-drlh) Dose:			Frequenc	·v·					
F. DIAGNOSIS INFORMATI												
Primary ICD Code:							de:					
G. CLINICAL INFORMATIO			=									
For ALL Requests (clinical do			nation made by completed	4	to <u>ortanoty</u> for all proc	oranoadon	roquosto.					
☐ Yes ☐ No Does the patie		· · · · · · · · · · · · · · · · · · ·	nosis of Hemophilia B (cor	ngeni	ital Factor IX deficienc	y)?						
☐ Yes ☐ No Will the requested medication be prescribed by or in consultation with a hematologist?												
Yes No Does the patie			X inhibitor test result within positive Factor IX inhibitor			20 daya fall	owed by a nego	tive teet recult				
The substitution in the substitution is the substitution in the substitution in the substitution in the substitution in the substitution is the substitution in the substitution in the substitution in the substitution in the substitution is the substitution in the substitution in the substitution in the substitution in the substitution is the substitution in the su			initial positive result?	i lesi	result within the past	ou days, ioii	owed by a nega	live test result				
☐ Yes ☐ No Has the patien		_										
☐ Yes ☐ No Does the patient have severe or moderately severe Factor IX deficiency (≤2% of normal circulating Factor IX)?												
☐ Yes ☐ No Is the patient currently using Factor IX prophylactic therapy? ☐ Yes ☐ No Does the patient have a current or a history of a life-threatening hemorrhage?												
☐ Yes ☐ No Does the patie			-		-							
H. ACKNOWLEDGEMENT												
Request Completed By (Sig	anature Rec	auired):		_			Date:					
Any person who knowingly fi						e with the i		defraud or deceive				

any insurance company by providing materially false information or conceals material information for the purpose of misleading, commits a fraudulent

The plan may request additional information or clarification, if needed, to evaluate requests.

insurance act, which is a crime and subjects such person to criminal and civil penalties.